Podcasts about Digital therapeutics

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that uses sound and light feedback to induce the unitary states therapists aim for in medicine sessions. We unpack the science of voice-activated biofeedback, ways to weave SoundSelf into preparation and integration protocols, and the larger promise of digital therapeutics for scalable, whole-person care.SoundSelf is a voice-guided, audio-visual platform that primes the nervous system for psychedelic-level surrender and supports post-session integration. Robin Arnott is the former CEO of Andromeda Entertainment, and author of The Technodelic Manifesto. Dr. Sandeep Prakash is a leading Psychedelic Researcher trained at California Institute of Integral Studies. Together they aim to set a new gold standard for tech-enabled mental health.Soundself is launching a new expansion: a tablet pre-configured with SoundSelf. Psychedelic Therapy Podcast listeners who order before May 9 2025 get this $600 upgrade free, plus a two-month evaluation window. Explore it for yourself at: www.soundself.com/ptpTimestamps:(03:46) The Origin and Evolution of SoundSelf(08:15) Exploring the Science and Application of SoundSelf(21:42) Voice Activated Biofeedback and Its Impact(30:47) The Role of SoundSelf in Psychedelic Therapy(35:43) Combining SoundSelf with Psychedelics(38:47) Future of Digital Therapeutics 

Kevin Malone, Member, Epstein Becker Green, speaks with Jenna Carl, Chief Medical Officer, Big Health, about developments in the use of digital therapeutics for mental health services. They discuss what digital therapeutics are, how they are used in patient care, ensuring safety and effectiveness, regulatory considerations, and the future of the field. From AHLA's Behavioral Health Practice Group.AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

ROMA (ITALPRESS) - Fornire ai medici un'adeguata preparazione nell'impiego delle terapie digitali. Questo il tema dell'audizione della Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri (Fnomceo) presso la Commissione Affari Sociali della Camera.sat/gtr

ROMA (ITALPRESS) - Fornire ai medici un'adeguata preparazione nell'impiego delle terapie digitali. Questo il tema dell'audizione della Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri (Fnomceo) presso la Commissione Affari Sociali della Camera.sat/gtr

Unlike general health and wellness apps, Prescription Digital Therapeutics (PDTs) are FDA-authorized, prescribed by healthcare professionals, and rigorously studied in clinical trials. With the global PDT market projected to reach $43 billion by 2032, new regulatory pathways, including CMS billing codes in 2025, are set to enhance adoption and accessibility.In his final episode hosting the Syneos Health Podcast, Nick Kenny is joined by Dr. Shaheen Lakhan, Chief Medical Officer, and Laura Taraboanta, Director of Medical Operations and Strategy, both from Click Therapeutics, to explore the evolving landscape of PDTs.Together, they discuss how PDTs work and for which conditions, the opportunities driven by the FDA's Prescription Drug Use-Related Software (PDURS) guidance—which now enables PDTs to be integrated into drug labels, where PDTs are making inroads to expand access to care, and a future that will include “software enhanced” (SE) drugs that improve adherence, personalization and treatment outcomes.The discussion underscores how PDTs are redefining personalized medicine, transforming healthcare delivery, and expanding into new therapeutic areas beyond mental health.For more from Click Therapeutics and our experts on Digital Therapeutics, check out:Syneos Health Podcast | Digital Therapeutic CommercializationSyneos Health Podcast | Digital Therapeutic Development and Approval10 Ways to Optimize and Accelerate Brand Performance using Prescription DTxHow Digital Therapeutics Developers Can Satisfy Diverse Stakeholder NeedsAbout Click SE™The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

How familiar are you with digital solutions for schizophrenia? Credit available for this activity expires: 12/17/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/understanding-and-managing-schizophrenia-digital-2024a1000mxz?ecd=bdc_podcast_libsyn_mscpedu

In this episode of the Crazy Wisdom Podcast, I, Stewart Alsop, sit down with Matt Omernick, a pioneer in leveraging interactive technology for health and cognitive improvement. We explore his journey from traditional game development to creating transformative digital therapeutics, touching on how technology like video games and AI is reshaping cognitive health, creativity, and human potential. Matt also shares his insights into the FDA approval process for these groundbreaking tools, discusses the role of creativity in a tech-driven future, and highlights the importance of ethical AI practices. For those interested in Matt's work, you can connect with him on LinkedIn to dive deeper into his ongoing projects.Check out this GPT we trained on the conversation!Timestamps00:00 Introduction and Guest Welcome00:29 Neuralink and Cognitive Impairment01:20 The Cognitive Crisis and Technology's Role03:18 Digital Therapeutics and AI Biometrics03:44 AI Augmentation and Creativity05:33 The Future of AI and Creativity08:02 Closed Loop Systems and Personalized Technology11:42 Generative AI and Ethical Considerations16:20 Art, Suffering, and Creativity19:30 The Human Element in AI20:10 Adaptability: Humanity's Strength and Weakness22:05 The Role of AI in Creative Fields23:08 Fragmentation and Tribalism in the Age of AI24:46 Evolutionary Biology and Human Adaptation28:14 Digital Health and Therapeutics30:33 Navigating the FDA Approval Process35:46 The Future of AI in Bureaucracy39:37 Conclusion and Contact InformationKey InsightsTechnology as a Tool for Cognitive Health: Matt Omernick highlights the transformative potential of interactive technologies like video games in addressing cognitive impairments. Once stigmatized, video games are now proving to be powerful tools in promoting mental health, supported by rigorous scientific evidence. These innovations open a new frontier in digital therapeutics, making it possible to create adaptive experiences that train the brain and yield measurable, durable improvements in cognitive function.The Role of AI in Creativity and Problem-Solving: AI is reshaping creativity by serving as an augmentation tool rather than a replacement for human ingenuity. Matt draws parallels to the introduction of tools like Photoshop, emphasizing that AI enables artists and creatives to work faster, experiment more, and push boundaries, while still relying on human input to guide its applications. This partnership between humans and AI is a significant shift, particularly in industries like gaming and digital art.The Cognitive Crisis of Overstimulation: Modern society faces a cognitive crisis driven by unprecedented levels of stimulation from technology. Matt discusses how primitive brain structures are struggling to cope with the demands of a hyper-connected world. However, instead of retreating from technology, he advocates leveraging it intelligently to create systems that help humans adapt and thrive in this new environment.FDA Approval as a Milestone for Digital Therapeutics: Achieving FDA approval for a video game-based therapeutic was a groundbreaking step, validating the legitimacy of this new form of medicine. The process involved creating a new regulatory framework tailored to digital products, blending the rigor of traditional clinical trials with the flexibility of software development. This achievement paves the way for future innovations in digital health.The Power of Closed-Loop Feedback Systems: Closed-loop systems, which continuously measure and adapt based on user input, are central to the success of digital therapeutics and other adaptive technologies. Matt explains how this approach not only optimizes cognitive training but also offers a model for creating highly personalized and effective interventions in health and wellness.Ethics and Responsibility in AI Development: Matt underscores the critical need for ethical practices in AI, particularly in creative fields. Protecting artists' rights, ensuring transparency in how AI is trained, and addressing potential biases are essential for fostering a future where technology serves humanity's best interests without exploitation or harm.A Hopeful Vision for the Future: Despite potential dystopian outcomes, Matt remains optimistic about the trajectory of technology. He believes humanity's adaptability and creativity will guide us toward solutions that enhance our lives and address major challenges. His work exemplifies this optimism, focusing on creating tools that blend technological sophistication with ethical and human-centered design principles.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Shizuko Morimoto, PsyD Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it's important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City. Reference: American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model Dr. Morimoto is a paid consultant of Otsuka. November 2024 US.UNB.X.24.00100

In this Keeping It Real Hot Take Jillian uncovers the truth about digital therapeutics—are they the future of healthcare, or just overhyped apps? Discover the pros and cons of these evidence-based tools, from accessibility and personalized care to privacy concerns and tech barriers. Tune in to find out if digital therapeutics could change the way you manage your health and what you need to know before diving in!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Ayesha spoke with Shaheen Lakhan, MD, PhD, Chief Medical and Scientific Officer, Click Therapeutics, a company focused on developing software as prescription medical treatments for people with unmet medical needs. Click Therapeutics is specifically developing Digital Therapeutics, which involve the delivery of prescription treatments to patient's smartphones. These are being developed for indications in psychiatry, neurology, oncology, immunology and cardiometabolic diseases. In collaboration with Otsuka, Click Therapeutics most recently developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. Dr. Lakhan, is an inventive entrepreneurial physician-scientist who is board-certified in neurology and pain medicine with over 20 years of industry experience. As Chief Medical and Scientific Officer at Click Therapeutics and a Board Director at SpineThera, he spearheads AI-enabled clinical development and drug-delivery platforms. Tune in to the episode to hear more the cutting-edge new field of digital therapeutics and how they are shaping the industry. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Robert McCarron, MD Guest: Arwen Podesta, MD Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That's why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association. Drs. McCarron and Podesta are consultants for Otsuka. September 2024 US.UNB.X.24.00073

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha. Dr. Emerson is a paid consultant of Otsuka. September 2024 US.UNB.X.24.00082

Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch their digital therapeutics products to market both seamlessly and with the patient in mind. That being said, we always stay up to date with the evolving landscape by attending meetings that bring together decision-makers with diverse expertise and fresh perspectives. LSX World Congress USA, which took place between September 11-12, 2024 in Boston, MA, addressed the complex investment, partnership, and innovation aspects of digital therapeutics. After attending the conference, Janelle Hart, managing editor, custom content at Citeline, sat down with principal and head of Digital Health & Access Innovation Strategy Tony Shi and consultant Eric Boyda from The Dedham Group, a Norstella company, to explore key takeaways from the meeting, what the future holds for digital therapeutics, and how Norstella and the Dedham Group are making strides in this sector to smooth the path from pipeline to patient. To listen to part 1 of this podcast, go to this link: https://soundcloud.com/citelinesounds/lsx-world-congress-usa-key-takeaways?si=6fa75aae9d7f45febcfe0bb6762a62aa&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing For more information on Norstella's capabilities as a healthcare technology partner, visit: https://www.norstella.com/ To learn more about the Dedham Group, contact Tony or Eric at: tony.shi@norstella.com or eric.boyda@norstella.com

在2019年發表於《新英格蘭醫學期刊》（New England Journal of Medicine）的重要文獻回顧中，對行動裝置在健康評估及數位治療領域的重要性進行了詳細的探討，這篇著重於行動裝置如何利用數位生物指標（Digital Biomarkers）與數位治療（Digital Therapeutics）來進行健康監控和疾病管理的文獻，可以幫助我們清楚掌握行動裝置應用於健康監測與評估時，幾個關鍵的基本概念。 這篇文獻介紹了兩種行動裝置蒐集使用者數據的方式：被動數據（Passive data）和主動數據（Active data）。被動數據通常是自動收集的，無需使用者主動輸入，例如智慧型手機和活動腕錶都能自動監測使用者的活動數據。相比之下，主動數據則需要使用者填寫問卷或輸入資訊。對於開發健康相關的應用程式，文章建議應優先使用被動數據，因其能持續獲取即時資訊且不影響使用者體驗。 數位生物指標在健康篩檢和治療追蹤中扮演關鍵角色，尤其針對憂鬱症、中風和糖尿病等疾病的管理。例如，結合行動裝置的應用程式，透過生態瞬時評估（Ecological Momentary Assessment, EMA）來進行即時的心理健康評估，可以有效提升診斷和追蹤效果。 同時，數位治療（Digital Therapeutics）將認知行為治療數位化，用於失眠、ADHD、藥物濫用等問題，透過智慧裝置的提醒和行為干預，幫助患者改善認知與行為。不同品牌和系統的裝置在數位治療中的差異，也為數位健康應用開發帶來挑戰，特別是在治療結果的一致性和可比性上。 最後，數位健康應用的發展同時面臨著數據收集及隱私保護的倫理挑戰。因此，如何在提供高效治療的同時，維持使用者隱私，將是所有想開發相關應用程式，以及這個領域未來發展的重要議題。 你對數位科技與健康監測、治療的議題有興趣或甚至也投入其中嗎？歡迎在本則貼文底下「留言」與我們交流你的看法，就有機會抽中節目中提到的這本《調查研究—方法與應用》關於「數據科學」的特刊喔！ 留言告訴我你對這一集的想法： https://open.firstory.me/user/cklmcyh2oc8o00885qdeluvr1/comments Powered by Firstory Hosting

Ryan Douglas is the co-founder of DeepWell DTx, a digital therapeutics venture lab dedicated to creating immersive experiences that address mental health challenges.Recently, DeepWell DTx achieved a major milestone: the U.S. Food and Drug Administration cleared five mental health apps, including DeepWell's software development kit (SDK). This marks the first time digital therapeutics have been approved for medical use, paving the way for games to be reimbursed through medical insurance.

Richard ‘RJ' Kedziora, Co-Founder, CEO, and Chief People Officer at Estenda Solutions, emphasizes that usability is critical in developing successful digital therapeutics, and industry standards and interoperability are essential for data sharing and integration. A digital therapeutic can be prescribed by a physician and reimbursed by insurance companies. It is a digital health application that has undergone clinical trials and regulatory review to prevent, monitor, or treat physical or mental health issues. The future of digital therapeutics looks promising, especially with Medicare's introduction of billing codes for prescription digital therapeutics. Richard explains, " I think of the difference between a digital health application and a digital therapeutic as the difference between supplements and medications prescribed by a physician. So as you know, there are any number of supplements on the market. Some have more evidence than less about whether or not they can prevent, treat, or monitor a specific disease condition." "Digital therapeutics, which can be prescribed, have gone through a rigorous evidencing process of clinical trials to make sure they work and have gone through regulatory review here in the U.S. by the FDA. So, they're an elevated category of digital health applications that have been created and can make a difference in the world." "You would still download them from the app store. That's still where you'll get them, but the key differentiator is probably from a billing perspective. Not only does that digital therapeutic meet a higher evidence-based, clinically-driven evaluation, but the idea is that you, as a patient individual, aren't paying for it and can be reimbursed by the insurance companies. That can make a real difference in how much money a company putting these out can invest in it and then sustain a business based on the digital health applications." #Estenda #DigitalHealth #DigitalHealthApps #DigitalTherapeutics #HealthTech #HealthcareTechnology #HealthcareIT #HealthcareInnovation #ArtificialIntelligence #HealthAI #Medtech estenda.com Download the transcript here

Richard ‘RJ' Kedziora, Co-Founder, CEO, and Chief People Officer at Estenda Solutions, emphasizes that usability is critical in developing successful digital therapeutics, and industry standards and interoperability are essential for data sharing and integration. A digital therapeutic can be prescribed by a physician and reimbursed by insurance companies. It is a digital health application that has undergone clinical trials and regulatory review to prevent, monitor, or treat physical or mental health issues. The future of digital therapeutics looks promising, especially with Medicare's introduction of billing codes for prescription digital therapeutics. Richard explains, " I think of the difference between a digital health application and a digital therapeutic as the difference between supplements and medications prescribed by a physician. So as you know, there are any number of supplements on the market. Some have more evidence than less about whether or not they can prevent, treat, or monitor a specific disease condition." "Digital therapeutics, which can be prescribed, have gone through a rigorous evidencing process of clinical trials to make sure they work and have gone through regulatory review here in the U.S. by the FDA. So, they're an elevated category of digital health applications that have been created and can make a difference in the world." "You would still download them from the app store. That's still where you'll get them, but the key differentiator is probably from a billing perspective. Not only does that digital therapeutic meet a higher evidence-based, clinically-driven evaluation, but the idea is that you, as a patient individual, aren't paying for it and can be reimbursed by the insurance companies. That can make a real difference in how much money a company putting these out can invest in it and then sustain a business based on the digital health applications." #Estenda #DigitalHealth #DigitalHealthApps #DigitalTherapeutics #HealthTech #HealthcareTechnology #HealthcareIT #HealthcareInnovation #ArtificialIntelligence #HealthAI #Medtech estenda.com Listen to the podcast here

In this week's Digital Health Roundup, Medtech Insight's Ryan Nelson highlights Click Therapeutics' FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics' personalized neuromodulation for Alzheimer's patients. Marion Webb discusses her interview with MindMaze's John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart's new symptom-tracking feature in their heart-focused app. Stories discussed in this episode: MindMaze, ‘A Ratio Of Luke Skywalker And R2-D2', Navigates The DTx Galaxy Click Therapeutics Anticipates Pharma Will Begin Developing Digital Drugs From Clinical Stage Sinaptica On Precision Neuromodulation To Combat Alzheimer's: ‘No Drug Dares Go After Moderate Patients' DHCoE-AI-Lifecycle-Management-Plan-To-Serve-As-Playbook-For-Standards Hello Heart Says Update To Cardiovascular Health Tracker Could Benefit Women Especially

Welcome to the DTx Podcast, where we explore the latest in digital therapeutics. In our previous episode with Mike Pace, we discussed the challenges facing DTx in 2023. Now, with positive developments in 2024, we're updating our community on the progress in advancing digital therapies. Host Eugene Borukhovich engages with experts Dr. Jenna Carl, Andy Molnar, Marty Culjat, and Kirsten Tullia to discuss the latest trends, challenges, and opportunities in the DTx industry. [00:30] Expanding US channels and mental health access [05:15] Software-wearable integration and commercial models [12:45] Coverage expansion impact on Medicare and Medicaid [18:10] Evolution of DTx and reimbursement challenges [23:30] Investor impatience and R&D impact [28:00] Medicare reimbursement and investor interest in DTx Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders. If you'd like to learn more about sponsorship opportunities across Mission Based Media assets, visit our website at https://missionbasedmedia.com/ Guest Links and Resources: Connect with Dr. Jenna Carl on Linkedin Connect with Andy Molnar on Linkedin Connect with Marty Culjat on Linkedin Connect with Kirsten Tullia on Linkedin Listen to the episode with Mike Pace Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode of Digital Therapeutics, host Simi Burn, PharmD engages in a deep conversation with Melanie Das, PhD, a San Francisco-based freelance Science and Medical writer specializing in fundraising for early-stage biotech startups. Melanie discusses her transition from bench scientist to freelance writer, focusing on the challenges and opportunities in digital health innovation, equity, and the role of AI in healthcare. Key Points Discussed: -Melanie's background as a bench scientist and transition to freelance Science and Medical writer -Insights on the protests against AI in healthcare by nurses and the need for inclusivity in technology adoption -Examples of AI perpetuating healthcare inequalities and the importance of inclusive technology development -Strategies for early-stage startups to effectively target messaging and secure funding -The disparity in venture capital funding for women of color and the need for educational reform in venture capital -Initiatives to empower women of color in digital health and promote diversity in healthcare innovation -Using LinkedIn and other digital platforms to become thought leaders and advocate for change Host: Simi Burn, PharmD LinkedIn: https://www.linkedin.com/in/simi-burn-pharmd/ Guest: Melanie Das, PhD LinkedIn: https://www.linkedin.com/in/melanie-das2023/ Website: https://www.consult-brainwaves.com/

Send us a Text Message.Digital therapeutics have experienced both significant promise and industry failures in equal measure.That being said, according to a recent PWC report, research found that more than half of patients are willing to use digital therapeutics and that more than 56% of doctors are recommending them to their patients.The need for digital therapeutics is clearly there, and patients are increasingly looking for personalized care.In this week's HealthBiz Briefs, Dr. Tryggvi Thorgeirsson, CEO of Sidekick, discusses how they're reinvigorating digital therapeutics with AI, personalized care, and new strategies for empowering patients.This episode is brought to you by BetterHelp. Give online therapy a try at https://betterhelp.com/caretalk  and get on your way to being your best self.As a BetterHelp affiliate, we may receive compensation from BetterHelp if you purchase products or services through the links provided.

Healthy Livers, Healthy Lives Chair Jeff Lazarus joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss some of the specific structural challenges that confront global MASLD public policy, along with some promising local activities. Louise observes that, in her experience, primary care practitioners appreciate the support that specialist nurses can bring in educating providers about the disease and patients about how to better support themselves. Jeff responds that these are good findings as individual cases, but to make major changes in the field, we need large-scale, top-down innovations. One thing that, oddly, works in MASLD's favor is that most patients with advanced MASLD will have concomitant diseases requiring involvement with other specialties. Today, teams are looking at system issues to find the largest, most intractable structural problems so that solutions can emerge. After that, "we'll start to see bigger and faster improvements in the field." Jeff talks about several positive things happening in New York. First, he mentions a New York Times article about junk food and how manufacturers target aggressive marketing to poor and marginalized populations, with the net result that these populations have processed and ultra-processed foods making up a large share of their diets. Also, a "visionary" health commissioner is creating a program, Healthy NYC, with the goal of increasing life expectancy by reducing specific diseases.MASLD is not part of the effort today but with clinician support. we can get there over time. Earlier, Jeff had commented about the ease of implementing the FIB-4 test. Now, Roger raises the issue again, this time mentioning that SurfingMASH guests from ex-US markets have mentioned that ALT is not a standard test in their countries and asks Jeff if MASLD is making progress here. Jeff discusses the debate around this issue.  

Healthy Livers, Healthy Lives Chair Jeff Lazarus joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss why political will is so important in overcoming inertia and obstruction in global MASLD public health policy.Louise notes that she left NHS because of obstruction against earlier stage efforts to promote liver health and asks how to achieve these goals. To Jeff, it all depends on political will. He provides an example from viral hepatitis to prove his point.Roger asks how to motivate primary care practitioners who are overloaded with tasks they need to complete during short, overly scheduled patient visits.Jeff notes this is a challenge today, with a solution that lies in education that not only teaches about the disease but also stresses the cost of inaction. To Jeff, teaching FIB-4 to primary care and automating the algorithm to make it available in every electronic patient record is the minimum we should strive for today.Jörn focuses on the cost of inaction from a different direction: physicians who are afraid they will demoralize patients when they diagnose a disease with no available treatment. Jeff responds, "Do we not raise awareness because we don't have out-of-the-box solutions?" He goes on to describe different types of solution that might work for a patient, ranging from digital apps to linking patients to social agencies that can provide support and services. Jeff notes that "the field will need to change as we find more patients," due to increased demand on public health systems and social agencies.

00:00:00 - Surf's Up: Season 5 Episode 22  Jeff Lazarus joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss Healthy Livers, Healthy Lives, a coalition of four major professional organizations (AASLD, ALEH, APASL and EASL) and other partners. This coalition works with other specialties to create global public health awareness and drive "top-down" solutions that are pivotal to stemming the MASLD Tsunami.  00:06:48 - The need for a MASLD public health coalitionJeff starts the conversation by describing the environment in which the MASLD community lives today: great news and energy within, but minimal exposure among related metabolic specialties and public health policy shapers. 00:11:55 -  Healthy Livers, Healthy LivesJeff describes the structure and goals of Healthy Livers, Healthy Lives.00:13:32 - Two initiatives to increase early screeningIn response to a question from Louise, Jeff mentions two efforts: a project to "double the diagnosis" over the next 3-4 years and another to identify all the concomitant conditions with sufficient disease cost to merit screening everyone living with that condition. 00:16:39 - Political will and structural changeLouise asks how we can overcome obstruction within the system to promote liver health. To Jeff, it all depends on political will, the energy that converts successful localized strategies into large-scale, top-down innovation. The solutions to the most significant, most intractable structural problems that evolve this way can drive "bigger and faster improvements in the field." 00:28:40 - Good things happening in New York In this context, Jeff shares how a visionary health commissioner in New York has created the Healthy NYC program to increase life expectancy by reducing specific diseases. 00:33:00 - The updated MASLD CPGJeff praises the updated MASLD CPG guidelines as "amazing" and suggests that one reason is that EASD and EASO are partners in drafting and promoting them.00:35:40 - Big Data-drive screening solutionsThis section explores whether and how Big Data can provide a set of standard variables that will outperform FIB-4 in predicting MASLD risk (see S5 E17). Jeff and Jörn identify the benefits and challenges of this approach.  00:38:38 - The upcoming U.N. General Assembly MASLD side eventHealthy Livers, Healthy Lives is holding this event at the U.N. General Assembly meeting in mid-September. The goal is to push the World Health Organization to develop and release a global health sector MASLD strategy.   00:40:41 - Presenting MASLD to politiciansOne challenge in educating policymakers about MASLD is that people do not die from MASLD. Sadly, large death counts produce public sector action, as we all saw with COVID-19. Suggestion: Reframing the issue as to how many people die with MASLD, not from MASLD, may make the story easier to tell.   00:43:06 - How listeners can support this initiative Roger asks Jeff how listeners can support the Healthy Livers, Healthy Lives initiative. Listen to hear Jeff's suggestions.   00:44:58 - LiverAIM and closing comments Jeff mentions LiverAIM, the largest European Commission-funded liver project in 26 years (see S5 E15). Jörn restates the importance of working with experts in developing public health approaches that drive policy change from the top down. Channeling Louise, Roger suggests that professional organizations need to bring allied health providers into the dialogue.   00:50:03 - Question of the Week Roger asks what listeners believe they can do in their own organizations and lives to support the goals discussed today.  00:50:36 - Business Report News on next week's session, Roger's office hours, and the Vault conversation.

Jillian Ahrens is the CPO at Realized Care, a digital therapeutics company specializing in VR solutions. She was formerly Associate Director of Product R&D at Pear Therapeutics, where she led a project developing a CBT-based AI chatbot.Discover what Jillian learned at Pear about patient engagement with AI chatbots, and how she's taking those lessons into her cutting-edge work delivering digital therapeutics for chronic pain.

Digital Therapeutics are an exciting space in health technology, and also in the shift to patient-centric care. Providing patients with tools, resources, and personalized insights on their smartphone or device, whenever and wherever they need it, promotes a sense of ownership, improves self-care behaviors, and leads to better health outcomes. And that can be life-changing, especially when it comes to mental health treatment. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

RJ Kedziora is the co-founder of Estenda Solutions, a leading company specializing in custom software and data analysis for healthcare and medical companies. With a remarkable journey spanning over 30 years, he possesses a deep understanding of designing, developing, and deploying successful software projects. His extensive experience enables him to provide valuable guidance and innovative insights, resulting in cost-effective solutions that improve patient outcomes. Mr. Kedziora received his M.B.A. from West Chester University and a Bachelor of Science in Computer Science from Duquesne University where he received the Excellence in Computer Science Award. He has spoken at numerous technical and healthcare conferences on a variety of topics and written or co-authored multiple articles focused on healthcare information technology, several published in peer-reviewed scientific journals. Social Media: RJ LinkedIn Estenda Estenda LinkedIn Driving Quality in Digital Health: The Role of Generative AI in Testing (Webinar – Friday, June 14th at 12pm) Mentioned in the show: The Price We Pay Instagram - Dannah_Eve (Safety Tips)

Dr. Dave Rabin, MD, PhD, is a neuroscientist, board-certified psychiatrist, health tech entrepreneur & inventor who has been studying the impact of chronic stress in humans for over 15 years. He is the co-founder & Chief Medical Officer at Apollo Neuroscience, which has developed the first scientifically validated wearable technology that actively improves sleep, relaxation, focus, and calm, using a novel touch therapy that signals safety to the brain. ___Get your copy of Personal Socrates: Better Questions, Better Life Connect with Marc >>> Website | LinkedIn | Instagram | Twitter Drop a review and let me know what resonates with you about the show!Thanks as always for listening and have the best day yet!*A special thanks to MONOS, our official travel partner for Behind the Human! Use MONOSBTH10 at check-out for savings on your next purchase. ✈️*Special props

About Syam Adusumilli:Syam is a seasoned healthcare leader and strategist, with deep product and strategy expertise across all business lines in Healthcare Payor Organizations. He has deep expertise in cutting-edge technologies, including Data Science and AI, Blockchain, Medical IOT, Voice Biometrics, Computational Epidemiology, Digital Therapeutics, Human Centric Design, Behavioral Nudge, and Care Plan Personalization. Syam has 30+ years of experience in technology and business strategy in healthcare, especially when it comes to managing IT operations, defining vision, strategic planning, partner ecosystems, and product engineering and management in the payor domain. He is seasoned in transforming organizations and driving innovations by leveraging digital and AI. As the current Chief Strategy Officer for GroundGame.Health, he is focused on go-to-market strategy, overall business strategy, and public policy. He is a Masters in Public Health candidate at Brown University and was previously the Chief Transformation Officer for Healthcare at UST Global. He serves as a mentor for several startups in HealthTech and beyond in the US, Israel, and India.Things You'll Learn:Digital transformation in healthcare is about focusing on the underserved population, bridging the gap in digital literacy, and addressing unmet needs.Technology should be a tool to empower social workers and community organizations, not replace human connection and empathy.Predictive AI should target the root causes of healthcare issues, not merely treat symptoms.Interoperability is crucial for providing comprehensive care, ensuring healthcare providers have access to patient's social and economic contexts.Empowering community-based organizations with technology and unrestricted funds has the potential to drive impactful change in underserved communities.Resources:Connect with and follow Syam on LinkedIn.Learn more about GroundGame Health on their LinkedIn and website.

Drs. Braham, Rogu, and Bravo have a fascinating real conversation about Digital Therapeutics. The intersection of digital innovations in pediatric healthcare with a focus on diagnosing and treating autism using AI technology like Canvas DX. It delves into challenges such as scarce specialists, early intervention's significance, regulatory processes, and the evolving role of pediatricians. Additionally, it addresses broader healthcare challenges, including insurance reimbursement complexities, policy considerations, and the pivotal role of collaboration and equity in improving patient outcomes. Dr. Sharief Taraman is the CEO of Cognoa, a leading pediatric behavioral health and data company developing AI-based technologies to enable early and equitable diagnosis and care for children living with developmental and behavioral health conditions.00:00 Welcome and Introduction to Pediatric Innovation Sessions00:33 Introducing Dr. Sharif Taraman: A Journey from Pediatric Neurology to Health Tech Leadership02:28 Exploring the Brain's Complexity and Digital Therapeutics04:21 The Evolution and Impact of Digital Diagnostics and Therapeutics07:05 Navigating the FDA Process and Addressing Pediatric Research Challenges14:01 The Real-World Application of Digital Health Tools in Pediatrics20:51 Addressing the Challenges of Pediatric Healthcare Delivery26:36 The Future of Pediatric Care: Digital Solutions and Systemic Changes32:24 Advocating for Early Prevention and the Role of Primary Care in Pediatric Health40:01 Understanding Care Coordination and the Importance of Early Detection41:13 Exploring the Multifaceted World of Care Coordination43:10 The Impact of Insurance in Care Coordination44:28 Navigating AI and Bias in Healthcare47:48 Innovating Autism Diagnosis with CanvasDX52:19 Challenges and Solutions in Medicaid Coverage01:05:37 The Future of Pediatric Care and Digital HealthSupport the show

The industry has a lot to figure out Right now, payer coverage of digital therapeutics is sparse. There are a few one-off contracts with state Medicaid plans, according to Health Affairs. Highmark, a Pittsburgh-based commercial payer with about 6 million members, covers some prescription digital therapeutics products. There are many things the industry needs to figure out to get more widespread payer coverage, according to Matthew Fickie, senior medical director at Highmark. For one, there's no standard among regulatory bodies on what exactly constitutes a digital therapeutic. https://www.healthcare-brew.com/stories/c/the-digital-therapeutics-industry-has-a-lot-to-figure-out-to-get-payer-coverage New boost

What do you know about the use of prescription digital therapeutics in psychiatry?    Credit available for this activity expires: 3/29/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000591?ecd=bdc_podcast_libsyn_mscpedu

On today's podcast, host Jonah Comstock is joined by Meri Beckwith, cofounder of Lindus Health, a next-gen CRO that includes digital therapeutics among its specialties. They talk a little bit about often unseen difficulties of validating a digital therapeutic through a clinical trial.

Ryan Douglas is the co-founder of DeepWell DTx, a digital therapeutics Venture Lab focused on creating immersive experiences that address mental health concerns.Ryan has created numerous medical devices, along with several profitable startups. He has deep experience with the regulatory landscape for digital therapeutics, and is pushing to get digital therapeutics accepted by the medical community.

Did you know that Belgium has had an idea for classifying and validating digital therapeutics since 2018? A clear framework was formed with all main stakeholders involved - from health insurance to the industry. So why are we not hearing more about DTx in Belgium? In this discussion you will hear from Dr. Steven Vandeput -  he is the Advisor for Digital MedTech and Services & Technologies Home Assistance in Belgium; he is managing the mHealthBelgium portal and, since 2019, has been a representative for beMedTech, the sector federation that represents the industry of medical technologies in Belgium.  Website: www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: 00:00 - Introduction 01:45 - Digital Therapeutics in Belgium 03:50 - Belgium's Healthcare Framework Development 06:00 - The Validation Pyramid and Reimbursement System 08:00 - Fate of Pilot Projects and Their Impact 10:00 - Utilization of mHealth Belgium Portal 12:00 - Challenges in Reimbursement and Financing 14:00 - Prospects for Digital Therapeutic Companies 16:00 - Belgium's Approach to Financing Digital Health 18:00 - Anticipations for the Digital Health Field 20:00 - The Evolving European Frameworks 22:00 - Impact of Political Decisions and Healthcare System Integration 24:00 - The Future of mHealth Belgium Platform

Studies show that over 65% of patients with chronic pain, Parkinson's Disease, post-acute stroke, and pelvic floor disorders do not fully recover with current treatments - resulting in hospital readmissions and ER visits. In this episode, we are joined by Siva Nadarajah, co-founder and President of JOGO Health, to share how more than a decade's worth of research and testing has been undertaken to address this problem through their digital rehabilitation solution. Promising early results have shown how several chronic residual disabilities can be treated via telemedicine using their platform. JOGO helps healthy brain cell networks rewire themselves to work with muscles that have become inactive due to stroke and other neuromuscular conditions. JOGO also helps break the pain-anxiety muscle tension cycle to reduce chronic and cancer pain. The power of neural plasticity is fully leveraged through their novel prescription digital therapeutic product composed of wearable wireless s/EMG sensors. A patent-protected mobile app uses AI and VR to provide treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuromuscular re-education. Siva also shares the origin story of the company, including the name “JOGO”, derived from Joe and Gordon - Dr. Joe Brudny and Dr. Gordon Silverman of New York University's Rusk Rehabilitation Center and Rockefeller University, respectively. Beyond the more recent research, Joe and Gordon established the underlying science more than 50 years ago, and the JOGO platform is now finally rewarding Joe and Gordon's legacy to offer new hope for patients across multiple disease domains. Tune in so you can learn how this pioneering work is drawing together entrepreneurs, product design specialists, technology enthusiasts, physical therapy professionals, physiatrists, data scientists, and game designers, to deliver an effective solution for patients. From democratizing healthcare, to international collaborations for Go-to-Market strategy, this discussion is packed with knowledge to keep you informed and inspired.

BIO: Chuck Hazzard is an entrepreneur and wearable expert. Chuck is currently working with Heads Up Health, the leading connected health platform being used for remote patient monitoring, precision medicine, and individuals seeking to achieve peak performance. Chuck is also an advisor to CardioMood, a Swiss-made, and clinically validated wearable device.In the past, Chuck has designed and built computer networks, developed software applications for large corporations, helped build a successful telecommunications business from the ground up, helped a large telecommunications company develop and bring to market products and services yielding an additional $500M in annual revenue, and most recently worked with Oura Ring during their early growth years.Chuck earned his BA in Computer Science and Mathematics from the University of Maine, where he also earned his JD at their School of Law. Chuck is also a graduate of the FDN program and is a licensed Heartmath Provider.SHOWNOTES:

In this episode of the DTx Podcast, Eugene Borukhovich hosts Philip Heimann, CEO of Vivira, a prominent player in the DTx landscape in Germany. "The genesis of Vivira was the need for personalized movement therapy - we wanted to provide people with a solution that was made just for them," says Philip.  This necessity led to the development of an innovative digital therapeutic solution that has made a significant impact in the market. Eugene and Philip dive into the profound impact of the DiGA law in Germany, passed in 2019, on Vivira's market growth. This legislation enabled general reimbursement and physician involvement in prescribing the app, marking a pivotal turning point for the company and the broader DTx landscape in Germany. In addition, Philip sheds light on the challenges faced by DTx startups in understanding the market complexities and securing suitable funders. He stresses the importance of selecting investors who can offer long-term support and emphasizes the significance of focusing on long-term goals and building high-value companies. 1. [05:30] What challenges did Vivira face in the early stages, being almost exclusively angel-funded, and how did this contribute to the development of their DTx solution? 2. [10:45] What pivotal role has the DiGA law played in enabling Viveira's growth in the market, and what are the implications of this legislation for other DTx companies in Germany? 3. [15:20] How has Vivira's approach of not starting in the direct-to-consumer market and focusing on the DIGA prescription model influenced its journey and success in the DTx space? 4. [20:10] What is the significance of high-quality clinical evidence, particularly RCT studies, for achieving permanent listing under the DiGA law? 5. [25:40] What are the challenges and potential solutions regarding the activation of digital therapies prescribed by doctors? 6. [30:15] As a serial entrepreneur, what critical advice does Philip have for DTX startups in navigating the complexities of the market and choosing investors? Join us on the DTx Podcast for valuable insights into the world of digital therapeutics, covering topics from legislative impacts to entrepreneurial advice. Subscribe now to stay updated on the latest episodes and continue exploring the dynamic realm of DTx. Guest Links and Resources: Connect with Phillip Heimann on LinkedIn Visit Vivira Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In honor of Gift of Sight month we're replaying this insightful episode with Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye's innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythyms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that's exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to “help people change some of those core beliefs, which then directly influence what we do on a day to day basis.” And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT – Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What's next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Curio has announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial demonstrating that MamaLift Plus has met its efficacy endpoints. This is a significant step towards providing better support for mothers during a crucial time.  In this Replay episode we hear from Shailja Dixit, CEO of Curio. In their own words: 'Curio is a Digital Therapeutics company with tailor-made Cognitive Behavioral Therapy programs for Women across the cycle of life – encompassing age groups, physiological conditions and social settings'. Topics include: The Founding Story of Curio Using Digital to Destigmatize Mental Health Support User experience of the MamaLift product Combining methods of Cognitive Behavioural Therapy, Interpersonal Therapy and Behavioural Activation Therapy  PDT vs Physician recommended DTx  Guest Links and Resources: Connect with Shailja Dixit on LinkedIn Visit https://www.curiodigitaltx.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | LSI | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this podcast episode, we delve into the critical topics of healthcare equity, digital therapeutics, and dismantling stigma in healthcare access. Our guest, Autumn Brennan, Director of Communications at the Digital Therapeutics Alliance (DTA), shares her insights into how digital health technologies can bridge gaps in healthcare access, particularly in rural and marginalized communities. We explore the challenges and opportunities in addressing healthcare disparities, focusing on the impact of digital therapeutics on mental health and marginalized groups. Autumn discusses her work in advocacy, legislative change, and messaging strategies to promote equitable healthcare access. Additionally, Autumn introduces the DTA's Evaluation Toolkit, which provides criteria to assess these tools, including clinical validation, data security, equitable access and more. It's a science-based resource to guide adoption. Key factors are evidence of improved outcomes and seamless integration into workflows. This toolkit enables informed decisions to provide patients high-quality, effective digital therapeutics. Join us for a thought-provoking conversation on these critical issues and gain valuable insights into healthcare equity, digital therapeutics, and compassionate communication in healthcare. About the guest As the Director of Marketing and Communications, Autumn leads the strategic marketing, public relations, and media efforts for the Digital Therapeutics Alliance, with the goal of building a unified, knowledgeable, and empowered community of stakeholders worldwide. Her experience spans product development and marketing strategies to advance dynamic, global business initiatives and drive innovation within EduTech, FinTech, Manufacturing, and Digital Health. Prior to her tech career, Autumn held a private practice in family medicine and midwifery, specifically within rural and marginalized communities. Her profound dedication to patient rights, healthcare equity, and social justice fuels her mission to see digital therapeutics reach their full potential to improve patient outcomes on a global scale. Resources DTA's Evaluation ToolkitHealioStat NewsMobi Health News Contact Autumn LinkedInhttps://dtxalliance.org/

In this special feed drop hear Eugene Borukhovich in conversation with Pharmaphorum Editor in Chief Jonah Comstock discussing what they saw and heard at DTx East in Boston. This year the digital therapeutics space took a hit with the downfall of Pear Therapeutics, one of the most well-known of the industry's still-active pioneers. Combined with Akili Interactive's hard pivot to OTC , some in the industry are wondering whether standalone prescription digital therapeutics are a failed experiment. Pharmaphorum Links and Resources: Connect with Jonah Comstock on LinkedIn Visit pharmaphorum.com Episode Write Up Pharmaphorum Podcast DTx Podcast Links and Resources:: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye's innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Therapeutics are software-based medical products designed to prevent, manage, or treat a medical disorder or disease. They use a variety of technologies, such as artificial intelligence, big data, and machine learning, to deliver personalized treatment and support to patients. CEO Robyn Hussa Farrel explains how Sharpen was co-founded by herself and her husband. They have reached a growth stage, having developed a radical approach to implementation of research focused on improving mental health disparities. Their online platform has been shown to (i) decrease risk and increase resilience, (ii) improve the shared protective factors for suicide, mental disorders and trauma, (iii) improve access to and utilization of quality mental health care, (iv) improve treatment outcomes among a variety of populations. Sharpen offers a library containing over 600 modules on over 200 mental health topics including over 4,000 peer-based videos. You can learn more HERE. We invite your feedback and suggestions at ventureinthesouth.com or email david@ventureinthesouth.com. If you like the podcast, leave us a review and share with your friends! Follow David and Paul on LinkedIn to stay updated on the newest episodes. To learn more about the RollingSouth Funds, visit rollingsouth.vc or email david@rollingsouth.vc. Thanks for listening and remember: Our mission is to MAKE MONEY, HAVE FUN AND DO GOOD

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process.  This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology.  Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics.

Guest: Dr. Bruce Y Lee, Executive Director of PHICOR (Public Health Informatics, Computational, and Operations Research) [@PHICORteam]On LinkedIn | https://www.linkedin.com/in/bruce-y-lee-68a6834/On Twitter | https://twitter.com/bruce_y_leeWebsite | https://www.bruceylee.com/On Forbes | https://www.forbes.com/sites/brucelee/On Psychology Today | https://www.psychologytoday.com/us/contributors/bruce-y-lee-md-mba_____________________________Host: Marco Ciappelli, Co-Founder at ITSPmagazine [@ITSPmagazine] and Host of Redefining Society PodcastOn ITSPmagazine | https://www.itspmagazine.com/itspmagazine-podcast-radio-hosts/marco-ciappelli_____________________________This Episode's SponsorsBlackCloak

As the U.S. struggles with a shortage of mental health providers, advocates say that digital therapeutics – evidence-based mental health treatments delivered via app -- could provide an important tool to expand access to mental health care. Vaile Wright, PhD, a clinical psychologist and senior director of healthcare innovation at the American Psychological Association, talks about how digital therapeutics work, how they're regulated, how they differ from other mental health and wellness apps, the kinds of mental and behavioral health conditions they can treat, and the role they might play in mental health treatment in the future. For transcripts, links and more information, please visit the Speaking of Psychology Homepage.